CLOs on the Move

Letco Medical

www.letcomedical.com

 
Since 1993 Letco Medical has been committed to providing compounding pharmacies complete customer satisfaction by offering the highest quality products, customer service, technical support and the fastest delivery times in the industry. Letco is your partner in compounding. We have an extensive line of chemicals, supplies, equipment, capsules, solutions and bases to support you. Letco Medical was also the first in our industry to offer CSOS ordering for your convenience. We also offer online ordering. We pride ourselves on knowing that satisfaction of a job well done is derived through a combination of hard work, perseverance and a thoughtful approach to do our best for our customers and our company. We communicate ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Regenxbio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

World Views Spatial Technologi

World Views Spatial Technologi is a Barrington, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.